Pipeline Database
UB274
Piperacillin Sodium and Tazobactam Sodium for Injection
UB274
ProductPiperacillin Sodium and Tazobactam Sodium for Injection
Strength0.5g: 0.125g; 1.0g: 0.25g; 2.0g: 0.5g; 0.5g: 0.0625g; 1.0g: 0.125g; 2.0g: 0.25g; 3.0g; 0.375g; 4.0g: 0.5g
IndicationsAppendicitis; Peritonitis; Skin infection; Soft tissue infection; Cellulitis; Skin abscess; Foot infection; Endometritis; Pelvic inflammatory disease; Community acquired pneumonia; Nosocomial pneumonia; Bacterial infection
TherapeuticsInfectious Diseases
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule
Exclusive Summary
- - Core patents expired years ago with widespread generics, enabling fast distribution entry and tender participation.
- - Addresses high-burden infections (cIAI, HAP/VAP, sepsis) with large, steady hospital demand.
- - Listed on the WHO EML and recommended by major guidelines as first-line/empiric therapy, supporting carbapenem-sparing strategies.
- - Although competition is crowded, recurrent supply shortages create room for reliable, full-portfolio suppliers to win tenders and substitutions.
- - Typically delivers 60–90% savings versus originator, fitting both GPO-driven and price-sensitive emerging markets.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →